John Hunt: EB or not EB - CRISPR/Cas9 Gene Therapy

CRIPSR-Cas9 genome editing is hindered by the low efficacyof correction and concerns regarding unwanted “off-target”editing. Here we develop an effective, low-risk, proof-of-principle, genome editing approach for epidermolysis bullosa,a group of rare fragile skin disorders. We can correct patient-specific mutations and grow robust lab-grown skin. 

This poster was uploaded for the SGS Research Showcase 2022.  

Choose your favourite poster for the SGS Research Showcase People's Choice Award: Academic Poster category.